Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
EyeGate Pharmaceuticals is a biotechnology business based in the US. EyeGate Pharmaceuticals stocks (EYEG.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.74 – the same closing value as a week prior. EyeGate Pharmaceuticals employs 14 staff and has a trailing 12-month revenue of around $12,059.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Since the stock market crash in March caused by coronavirus, EyeGate Pharmaceuticals's stock price has had significant negative movement.
Its last market close was $1, which is 86.11% down on its pre-crash value of $7.2 and 250.00% down on the lowest point reached during the March crash when the stocks fell as low as $3.5.
If you had bought $1,000 worth of EyeGate Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $620.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $166.67.
|Latest market close||$1.00|
|52-week range||$0.80 - $7.85|
|50-day moving average||$1.86|
|200-day moving average||$3.47|
|Wall St. target price||$11.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.63|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2022-01-05)||N/A|
|1 month (2021-12-15)||11.41%|
|3 months (2021-10-15)||-48.45%|
|6 months (2021-07-16)||-69.42%|
|1 year (2021-01-15)||-83.95%|
|2 years (2020-01-15)||-86.03%|
|3 years (2019-01-15)||82.22%|
|5 years (2017-01-13)||1.56|
|Gross profit TTM||$-3,553,986|
|Return on assets TTM||-40.35%|
|Return on equity TTM||-103.8%|
|Market capitalisation||$24.7 million|
TTM: trailing 12 months
We're not expecting EyeGate Pharmaceuticals to pay a dividend over the next 12 months.
EyeGate Pharmaceuticals's shares were split on a 1:15 basis on 29 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyeGate Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for EyeGate Pharmaceuticals shares which in turn could have impacted EyeGate Pharmaceuticals's share price.
Over the last 12 months, EyeGate Pharmaceuticals's shares have ranged in value from as little as $0.8002 up to $7.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyeGate Pharmaceuticals's is 0.7974. This would suggest that EyeGate Pharmaceuticals's shares are less volatile than average (for this exchange).
EyeGate Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.